By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.

Key Statistics

Ownership: Public

Web Site: AbbVie
Symbol: ABBV


Company News
Biogen (BIIB) And AbbVie (ABBV) Receive Positive Opinion From The CHMP On ZINBRYTA (Daclizumab) For Treatment Of Multiple Sclerosis 4/29/2016 10:11:01 AM
AbbVie (ABBV) To Present At The Bank of America (BAC) Merrill Lynch 2016 Global Health Care Conference 4/29/2016 8:23:19 AM
AbbVie (ABBV) Release: European Medicines Agency Issues Positive Opinion For The Use Of IMBRUVICA (Ibrutinib) As A First-Line Treatment For Chronic Lymphocytic Leukemia Patients 4/29/2016 7:32:15 AM
AbbVie (ABBV) Reports First-Quarter 2016 Financial Results 4/28/2016 7:01:29 AM
AbbVie (ABBV) Pays $5.8 Billion+ for Bay Area's Stemcentrx, Which Has Ties to Paypal and SpaceX Investors 4/28/2016 5:59:03 AM
Rumors Surface Again About AstraZeneca PLC (AZN), Sanofi (SNY) or AbbVie (ABBV) Acquiring Medivation (MDVN) 4/26/2016 7:00:15 AM
Enanta Pharmaceuticals, Inc. Announces FDA Has Approved AbbVie (ABBV)’s Supplemental New Drug Application For Use Of VIEKIRA PAK Without Ribavirin In Genotype 1b Chronic Hepatitis C Patients With Compensated Cirrhosis 4/25/2016 8:34:19 AM
Deal Spree for AbbVie (ABBV) Continues with $500 Million Cancer Tie-Up with Bay Area's CytomX 4/22/2016 6:16:31 AM
UCL And ARGENX Collaboration Lands A Major Deal In The Field Of Immuno-Oncology With AbbVie (ABBV) 4/21/2016 6:09:37 AM
AbbVie (ABBV) Release: Data Presented At AAN Highlight Impact Of ZINBRYTA (Daclizumab HYP) On Cognitive Outcomes And The Reversibility Of Its Targeted Mechanism Of Action 4/20/2016 11:31:34 AM